Company intelligence / Profile preview

Black Bear Fund I

San Rafael, California, United States

Ownership: Private
Development stage: Other

Overview

Black Bear Fund I, L.P. was an investment fund managed by Eastbourne Capital Management, L.L.C., led by founder Richard Jon Barry. The fund gained significant notoriety in the life sciences sector for its activist investment strategies and high-profile involvement in the corporate governance of major biotechnology companies. Most notably, Black Bear Fund I was a central participant in the 2009 proxy contest at Amylin Pharmaceuticals, where it advocated for a change in leadership to optimize the commercialization of the company's diabetes pipeline, including Byetta and Bydureon. The fund also held substantial positions in other healthcare entities, such as AVI BioPharma (now Sarepta Therapeutics), influencing strategic directions within the RNA therapeutics space.

Industry: Investors

Beyond the preview

Go deeper on Black Bear Fund I.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Black Bear Fund I.

Explore the full profile